tirzepatide weight loss percentage surmount trials (Zepbound; Eli Lilly and Co) demonstrated 47% greater relative compared to semaglutide (Wegovy; Novo Nordisk) in the SURMOUNT-5 phase 3b open-label trial. Full results will be presented at a Semaglutide vs tirzepatide vs retatrutide:

Whats inside the box

While large randomized trials do not specifically measure UTI incidence, mechanistic studies show GLP-1 agonists reduce fluid intake, concentrate urine, and alter glucose handlingall factors that increase UTI risk

In pulmonary vein cardiomyocytes (Chan et al., 2023), GLP-1 amide modulates ionic currents by decreasing L-VGCC and Na + /Ca 2+ exchanger current while increasing sarcoplasmic reticulum Ca 2+ content

Researchers still need to confirm long-term safety, identify which patients benefit most, understand how weight changes are maintained over time, and compare outcomes fairly with other established therapies

Commercial registeration number 2053102301 The VAT number 302263187200003 Business Certificate 0000205669